Active Filter(s):
Details:
The proceeds will advance the development of Re-Vana’s novel and proprietary photo-crosslinked EyeLief®, EyeLief-SD™ and OcuLief® biodegradable drug delivery technologies and will enable expansion of the company’s operations and development teams.
Lead Product(s): Undisclosed
Therapeutic Area: Ophthalmology Product Name: Undislosed
Highest Development Status: Undisclosed Product Type: Undisclosed
Partner/Sponsor/Collaborator: Visionary Ventures
Deal Size: $11.9 million Upfront Cash: Undisclosed
Deal Type: Series A Financing December 06, 2022